You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: August 2020 to March 2024

AbstractFullPdf
Aug 202021321385
Sep 202017117164
Oct 2020757526
Nov 2020656627
Dec 2020505013
Jan 2021353510
Feb 2021282811
Mar 2021282815
Apr 2021292918
May 2021202021
Jun 2021252513
Jul 2021343416
Aug 2021303016
Sep 2021333324
Oct 2021333434
Nov 2021292927
Dec 2021313114
Jan 2022525317
Feb 2022424412
Mar 2022323617
Apr 2022404516
May 2022788017
Jun 2022616825
Jul 2022293216
Aug 2022484819
Sep 2022343616
Oct 2022464826
Nov 2022313111
Dec 2022161610
Jan 2023212112
Feb 202342427
Mar 2023181914
Apr 202315155
May 202321216
Jun 202321211
Jul 2023101010
Aug 202316166
Sep 202313136
Oct 2023262611
Nov 2023323211
Dec 202325255
Jan 2024141512
Feb 2024191911
Mar 2024131357
Total17441776810